Baiteng Zhao Acquires Shares in Whitehawk Therapeutics

On June 12, 2026, Baiteng Zhao made a notable move by purchasing 38,040 shares of Whitehawk Therapeutics, Inc. (NasdaqCM: WHWK). This insider buying activity adds to the interest in the biotechnology company, which is working on innovative cancer treatments.

Other Institutional Activity in Whitehawk Therapeutics

Several institutional investors have maintained their positions in Whitehawk Therapeutics. QVT Financial LP holds 4,615,709 shares valued at approximately $15.9 million. Similarly, Orbimed Advisors LLC holds 4,166,000 shares worth about $14.4 million. Suvretta Capital Management, LLC has a stake of 3,700,000 shares, valued at roughly $12.8 million. Acuta Capital Partners, LLC owns 3,410,402 shares valued at $11.8 million, while Avoro Capital Advisors LLC holds 2,849,402 shares worth about $9.8 million.

Whitehawk Therapeutics Stock Snapshot

Shares of Whitehawk Therapeutics (NasdaqCM: WHWK) traded around $4.16 recently. The company has a market cap of approximately $202.8 million. Its stock has seen a 52-week low of $1.57 and a high of $5.495. Whitehawk Therapeutics boasts a current ratio of 11.356, reflecting strong liquidity.

Recent Earnings

Whitehawk Therapeutics, Inc. is not yet profitable, with an EPS of -$2.49. The company's return on equity is -68.54%, and it has a net margin of 0.0%. Investors are looking ahead to the next earnings report due on August 6, 2026.

Insider Buying and Selling at Whitehawk Therapeutics, Inc.

On June 12, 2026, several insiders, including Castelein Caley, Desai Neil, Reeve Emma, Maroun Richard, Zhao Baiteng, and Aghazadeh Behzad, each acquired 38,040 shares of Whitehawk Therapeutics. These purchases were not part of a pre-planned trading program.

Analysts Set New Price Targets

On April 16, 2026, Citizens initiated coverage of Whitehawk Therapeutics with a 'buy' rating and an $8.00 price target. Previously, on December 22, 2025, Jones Trading also started coverage with a 'buy' rating and a $7.00 target. The consensus among analysts is a 'buy' rating with an average target price of $6.50.

About Whitehawk Therapeutics

Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company based in Morristown, New Jersey. It focuses on developing next-generation antibody-drug conjugates (ADCs) to treat cancer. Led by CEO Dr. David J. Lennon, the company aims to advance oncology therapeutics by leveraging its expertise in tumor biology.

Bottom Line

The recent insider buying activity by Baiteng Zhao and others at Whitehawk Therapeutics highlights ongoing interest in the company's future prospects. With a market cap of around $202.8 million and a 'buy' consensus among analysts, investors continue to monitor this clinical-stage biotech firm. Keep in mind that insider transactions are disclosed after the fact and may not indicate current trading intentions.